Drug development is among the slowest, most failure-prone processes in modern science. Even with today’s tools, about 90% of drug candidates never reach the market. That number matters because it frames every conversation in pharma and biotech, from board meetings to capital allocation. The first question is not “can we innovate?” It is “where exactly does innovation reduce risk, and where does it not?”

A promising answer is showing up in the earliest stage of the pipeline: using AI to speed up drug discovery by “plucking promising molecules out of endless possibilities.” Researchers are applying AI methods to narrow the universe of candidates faster than traditional approaches, so teams can spend time and money on molecules with a better shot at moving forward. But the headline promise stops there, because drug success depends on far more than picking a good-looking starting point.

To see why the 90% figure still looms, it helps to understand what “success” really means. A successful drug must be not only safe and effective, but also able to bypass the body’s defenses and reach the right target. Those requirements create a chain reaction of tests. Even if AI improves the first step, every later step adds new ways for a molecule to stumble. It might fail because it does not reach the intended target at the right time or dose. It might fail because the body’s defenses block it or because the target biology does not respond as expected. And then there is the overarching regulatory reality: the bar for safety and efficacy is not negotiated down simply because discovery went faster.

AI’s value, at least today, is concentrated in the “search” phase. Drug discovery is often described as combing through enormous chemical spaces. Without smart triage, researchers can drown in options. AI can compress that search, turning an overwhelming number of possibilities into a smaller set of candidates that are more worth investigating. That changes operational tempo. It can shorten how long teams wait before learning something meaningful. It can also reduce the number of expensive experiments needed to find out a molecule is not a fit.

But speed in early discovery does not automatically solve the later bottlenecks. The next stages are still biological and physical reality in action. A molecule has to work in the context of the entire organism, not just in a model. It has to navigate delivery barriers, metabolism, and distribution. It has to reach the right target, which is not just a location problem but also a timing and concentration problem. And it has to do so while remaining safe. In other words, AI can help teams choose candidates faster, but it cannot remove the obligation to prove performance and safety.

Regulators also effectively “time-lock” progress. Drug development is not only science. It is compliance and evidence. Faster discovery can help a company design smarter studies and potentially arrive at investigational candidates sooner, but clinical and regulatory review still require robust data. That means companies must treat AI like an efficiency tool, not a waiver. Boards and investors should expect that AI may improve the odds of getting through the first filters while the overall attrition story remains governed by the same fundamental biology and the same safety and efficacy thresholds.

This is where second-order implications show up for decision-makers. When AI accelerates discovery, teams are pressured to capitalize on that momentum. That can be good, because delays between stages can compound costs and erode learning. But it can also create a mismatch if the downstream organization, like assay capacity, translational work, or clinical planning, does not scale at the same speed. The pipeline can start moving faster, yet still hit the same real-world walls. So the operational question becomes: how do you pair AI-enabled selection with the capacity to validate, de-risk, and document?

The strategic stakes extend beyond one lab or company. If researchers can consistently “pluck promising molecules” earlier, the competitive advantage shifts toward organizations that can convert those early gains into later evidence. For peers in similar roles, the test is not whether AI exists. It is whether it changes outcomes in a way that matters to regulators, clinicians, and ultimately the market. Given that about 90% of candidates still never reach it, executives should treat AI as a speed-up to reduce waste in early selection, while planning for the fact that safety, efficacy, target engagement, and delivery barriers remain the ultimate gatekeepers.